Predict the survival of COVID-19 hospitalized patients!
Our PeptiCov kit enables the prediction of survival of COVID-19 hospitalized patients.
The PeptiCoV Proteomics kits provides a thorough MRM-MS strategy with paired labeled and unlabeled peptide standards to ensure robust, reproducible, and interference-free measurements of 10 biomarker proteins. These easy-to-use kits enable you to perform precise protein quantitation using your own in-house LC-MS/MS instrumentation. The concentrations of the 10 biomarker proteins allow the prediction of survival of COVID-19 patients on the day of hospitalization with 80% accuracy.
Representative extracted ion chromatograms (XICs) of the biomarker-derived peptides quantified by the PeptiCoV kit to predict COVID-19 patient survival.
Paired heavy/light peptide quantitation strategy
High quality MRM-MS technology, with all assays characterized according to Tier II CPTAC guidelines
High purity paired heavy/light peptide standards for every targeted protein
Compatible with sample volumes as low as 10 µl of plasma
A complete turnkey solution for quantitative proteomics
Each kit includes
Heavy SIS and light peptide standard mixes
Includes BSA and trypsin
Quality control samples
Kit Manual with all required SOPs
USB with all required acquisition methods and worklists for selected instrument
Analysis instructions with Skyline templates for automated data analysis
How to order
Order kit through contacting us at firstname.lastname@example.org.
Our complementary line of quality control products will help to ensure that your proteomics workflow and instrumentation is up to standard for every sample you analyze.
PeptiQuant™ Plus technology is also offered in a full-service format, allowing for quantitation of up to 375 proteins in a single multiplexed analysis.
Richard VR, Gaither C, Popp R, Chaplygina D, Brzhozovskiy A, Kononikhin A, Zahedi RP, Nikolaev E, Borchers CH
Targeted mass spectrometry assays were characterized at the UVic-Genome BC Proteomics Centre according to the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) assay characterization guidelines (https://assays.cancer.gov/guidance-document). Initial characterization data (produced in a human plasma matrix), can be viewed on the CPTAC Assay Portal (https://assays.cancer.gov). Note: Specific kits may use a different type of matrix from the human plasma that was used to generate the CPTAC fit-for-purpose characterization data, and thus assay performance from this kit may vary from that reported on the CPTAC Assay Portal. The CPTAC assay characterization guidance documents were developed as a direct outcome of a workshop (Carr et al., Mol Cell Proteomics 2014; PMID 24443746) sponsored by the CPTAC program.